Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Assets (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Non-Current Assets for 14 consecutive years, with $110.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 25.91% year-over-year to $110.2 million, compared with a TTM value of $524.3 million through Dec 2025, down 27.01%, and an annual FY2025 reading of $110.2 million, down 25.91% over the prior year.
  • Non-Current Assets was $110.2 million for Q4 2025 at Fate Therapeutics, down from $122.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $302.4 million in Q2 2021 and bottomed at $110.2 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $199.5 million, with a median of $192.5 million recorded in 2023.
  • The sharpest move saw Non-Current Assets soared 166.74% in 2021, then crashed 33.71% in 2025.
  • Year by year, Non-Current Assets stood at $288.0 million in 2021, then decreased by 29.36% to $203.5 million in 2022, then fell by 14.16% to $174.7 million in 2023, then fell by 14.82% to $148.8 million in 2024, then decreased by 25.91% to $110.2 million in 2025.
  • Business Quant data shows Non-Current Assets for FATE at $110.2 million in Q4 2025, $122.4 million in Q3 2025, and $141.2 million in Q2 2025.